NASH Companies Take The Stage At AASLD
AASLD Round-Up: NGM, Inventiva, Albireo Among The Companies Progressing In NASH
NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.
You may also be interested in...
NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.
89Bio thinks its Phase II FGF21 analog could prove best-in-class in NASH due to a longer half-life than Bristol’s pegbelfermin, and avoid the LDL-increasing effects seen with NGM’s FGF19 analog.
Atypical histological findings from a Phase IIb NASH study lead CymaBay to terminate mid-stage studies in NASH and PSC and place a Phase III PBC trial on hold.